Ayahuasca is a modern, autoflowering variety developed from Ruderalis genetics. As a strain designed for accessibility, it is characterized by an easy difficulty level for cultivation. Growers can expect a flowering phase of approximately 63 days, with the plant performing well in both indoor and outdoor environments, though it is noted for a low overall yield. Its genetic contribution to the industry includes the notable offspring Monster Bud XL.

The terpene profile of Ayahuasca is complex, led by a dominant concentration of myrcene, followed by caryophyllene and limonene. The sensory experience is further rounded out by the presence of pinene, terpinolene, linalool, beta-pinene, humulene, nerolidol, and ocimene. Trace secondary compounds, including bisabolol, guaiol, camphene, caryophyllene-oxide, and p-cymene, complete the chemical composition. This diverse aromatic profile provides a distinctive experience that is reflective of its specific terpene-forward internal structure.

As a THC-dominant variety, Ayahuasca produces effects described as relaxed, happy, and uplifted. These characteristics make it a functional choice for managing stress and pain, while also providing utility for those seeking assistance with sleep. By combining the convenience of an autoflowering growth cycle with these therapeutic outcomes, the strain occupies a specific niche within modern cannabis genetics.